Your session is about to expire
← Back to Search
Ketone Ester
12.5 g/d of C6 ketone di-ester for Pharmacokinetics
N/A
Waitlist Available
Led By Dawn Beckman, MD
Research Sponsored by BHB Therapeutics, Ireland LTD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-8 hours
Awards & highlights
Study Summary
Randomized, parallel repeat dose pharmacokinetic study of C6 ketone di-ester in a ready to drink beverage matrix.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0-8 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-8 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Area under the curve (AUC)
Cmax
Elimination half-life
+1 moreTrial Design
3Treatment groups
Active Control
Group I: 12.5 g/d of C6 ketone di-esterActive Control1 Intervention
Low dose of ketone di-ester.
Group II: 25 g/d of C6 ketone di-esterActive Control1 Intervention
Middle dose of ketone di-ester.
Group III: 50 g/d of C6 ketone di-esterActive Control1 Intervention
Highest dose of ketone di-ester.
Find a Location
Who is running the clinical trial?
BHB Therapeutics, Ireland LTDLead Sponsor
2 Previous Clinical Trials
102 Total Patients Enrolled
1 Trials studying Pharmacokinetics
12 Patients Enrolled for Pharmacokinetics
Mérieux NutriSciences BiofortisUNKNOWN
1 Previous Clinical Trials
12 Total Patients Enrolled
1 Trials studying Pharmacokinetics
12 Patients Enrolled for Pharmacokinetics
Dawn Beckman, MDPrincipal InvestigatorMérieux NutriSciences Biofortis
8 Previous Clinical Trials
451 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger